Abstract
Ocrelizumab represents a generally well-tolerated, high-efficacy disease-modifying therapy (DMT) approved in Czech Republic for the RRMS. The aim of this study was to evaluate the cost-effectiveness of ocrelizumab compared with other DMT (glatiramer acetate, interferon beta-1a, interferon beta-1b, teriflunomide) for the treatment of RRMS from payer perspective.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
